Kornimate/medical-research-clean huggingface dataset:
heat waves and the elderly with copd

Conditions: COPD; Aging; Hyperthermia

Summary: the purpose of this study is to investigate thermoregulatory responses in older individuals with copd.

heat waves are the leading cause of death among natural disasters in the united states. elderly individuals are disproportionately more likely to become ill or die during heat waves. while the elderly have a reduced ability to regulate their body temperature,8-10 hospitalizations and deaths in this population during heat waves are primarily due to cardiovascular and/or respiratory complications, not solely hyperthermia. while previous research has primarily focused on the thermal and cardiovascular consequences of healthy aging, very little research has focused on the physiological responses to heat exposure in older individuals with chronic disease, such as chronic obstructive pulmonary disease (copd). notably, epidemiological data suggests that pulmonary complications are a leading cause of heat wave-related hospitalizations in older adults with a diagnosis of copd, yet nothing is known regarding the physiological mechanisms by which those with copd are most susceptible to heat waves. to fill this important gap, the investigators will identify the physiological responses that occur in this population, relative to healthy age-matched individuals, during two unique heat wave simulations.

Eligibility criteria:
inclusion criteria: * 65 years old or older * diagnosis of copd exclusion criteria: * known heart disease * other chronic medical conditions requiring regular medical therapy including cancer, diabetes, uncontrolled hypertension, and uncontrolled hypercholesterolemia etc * abnormality detected on routine screening suggestive of provokable ischemia or previously undetected cardiac disease or resting left bundle branch block on screening electrocardiogram * current smokers * participant with a body mass index ≥31 kg/m2

Keywords: copd heat wave thermoregulation
effectiveness of infiltrations in the treatment of plantar fasciopathy

Conditions: Plantar Fasciitis of Both Feet; Plantar Fasciopathy

Summary: this clinical study aims to evaluate the effectiveness of infiltrations in the treatment of plantar fasciopathy, a painful condition that affects the sole of the foot and is common in active people. plantar fasciopathy is caused by inflammation or damage to the plantar fascia, the tissue that connects the heel to the toes. participants in this study will be randomly assigned to receive one of two treatments: corticosteroid infiltrations or conservative treatment without infiltrations. infiltrations will be guided by ultrasound to ensure accuracy. the study will evaluate pain reduction and improvement in foot function over a six-month period. the objective of the study is to determine if infiltrations provide a significant improvement compared to other non-invasive treatments. the results will help doctors and patients make informed decisions about the best treatment options for plantar fasciopathy.

this clinical study, titled \&#34;effectiveness of infiltrations in the treatment of plantar fasciopathy\&#34;, will be carried out at the university of seville and its main objective is to evaluate the impact of corticosteroid infiltrations on pain reduction and functional improvement in patients diagnosed with plantar fasciopathy.

Eligibility criteria:
inclusion criteria: age: participants aged 18 to 50 years. diagnosis: confirmed diagnosis of plantar fasciopathy based on clinical evaluation and imaging (if applicable). duration of symptoms: symptoms persisting for at least 6 weeks prior to enrollment. pain level: reported pain level of at least 4 on the visual analog scale (vas) at baseline. ability to comply: participants must be able to follow study protocols and attend follow-up appointments. informed consent: participants must provide written informed consent to participate in the study. exclusion criteria: other foot pathologies: presence of other significant foot conditions (e.g., fractures, arthritis, tarsal tunnel syndrome) that could interfere with the study results. pregnancy or breastfeeding: pregnant or breastfeeding individuals will be excluded from the study. neurological disorders: history of significant neurological disorders affecting lower limb function. systemic conditions: patients with systemic conditions (e.g., diabetes, autoimmune diseases) that could affect healing or response to treatment. allergy to corticosteroids: known allergy or adverse reaction to corticosteroids or local anesthetics. psychiatric disorders: individuals with severe psychiatric disorders that may impair their ability to provide informed consent or adhere to the study protocol.

Keywords: plantar fasciitis fasciopaty corticosteroid prp hyaluronic acid infiltrations treatment
anterior corneal striae in hypotony

Conditions: Hypotony Ocular; Cornea Folds and Rupture of Bowman's Membrane Both Eyes; Maculopathy

Summary: the goal of this is to evaluate the biomechanical properties of hypotonous eyes with vertical anterior corneal striae and/or hypotony maculopathy compared to hypotonous eyes without striae.


Eligibility criteria:
inclusion criteria: * subjects \>= 18 years of age * history of glaucoma * history of glaucoma surgery * intraocular pressure of equal to or less than 10 mm hg by goldmann applanation exclusion criteria: * coexisting ocular disease that may affect ocular biomechanics, including macular disease, corneal transplant, and uveitis
caratkids: italian validation of asthma and allergic rhinitis control test in children

Conditions: Allergic Rhinitis; Asthma

Summary: this project is an observational study for the italian language validation of the caratkids questionnaire investigating the asthma and coexisting allergic rhinitis control in children. 113 patients with concomitant asthma and allergic rhinitis followed up from at least 3 months will be enrolled for the validation process at outpatient clinic of pediatric allergology \& pulmonology (pap) of respiratory disease research center (rdrc) within the institute of biomedicine and molecular immunology (ibim) of the national research council (cnr) of palermo (rdrc-ibim cnr), italy. the study will be completed in two medical examination, within 3-6 weeks of each other. caratkids questionnaire, vas (visual analogic scale) and c-act (children asthma control test) will be filled by each patient. the main outcome is the italian language validation of the caratkids questionnaire investigating the coexisting asthma and allergic rhinitis control in children.


Eligibility criteria:
inclusion criteria: * 113 patients with concomitant asthma and allergic rhinitis followed up from at least 3 months * 12 \ 6 exclusion criteria: * patients with asthma only or allergic rhinitis only, or younger or older than the targeted age group

Keywords: allergic rhinitis asthma children control
application of pne in postoperative pain management of patients with primary total knee arthroplasty

Conditions: Pain

Summary: this study intends to carry out pain neuroscience education intervention for tka patients to clarify the effect of this method on the degree of postoperative pain, the incidence of pain catastrophizing, kinesiophobia, and knee joint function rehabilitation in tka patients, so as to provide a basis for clinical nursing of such patients.


Eligibility criteria:
inclusion criteria: 1. patients diagnosed as koa according to the criteria and undergoing unilateral total knee arthroplasty for the first time; 2. the subjects included in this study were men or women aged 45-74 years; 3. clear self-cognition, can browse the text by themselves or can answer questions correctly; 4. those who voluntarily participated in the study and signed an informed consent form after understanding the relevant information of the study; 5. without serious physical diseases such as heart, liver or kidney; 6. no history of mental illness or drug dependence. exclusion criteria: 1. combined with severe trauma in other parts; 2. accompanied by serious damage to other organs, such as heart and cerebrovascular diseases, lung and kidney diseases; 3. patients with knee tumor and severe knee deformity who could not complete the rehabilitation; 4. with neurological diseases that limit physical activity; 5. participating in other investigators during the same period.
double-blind, randomized, placebo-controlled comparison of cc-10004 in subjects with moderate to severe plaque type psoriasis

Conditions: Psoriasis

Summary: there is an unmet medical need for safe, effective oral therapy for moderate-to-severe psoriasis. cc-10004 will be evaluated in a controlled setting of a clinical study. the information obtained from the study will aid in the design of future clinical trials and to establish the safety and efficacy of cc-10004.


Eligibility criteria:
inclusion criteria: * must understand and voluntarily sign and informed consent form * must be in good health as judged by the investigator * must be able to adhere to the study visit schedule and other protocol requirements * must have greater than or equal to a 6 month history of moderate-to-severe plaque-type psoriasis * must have a psoriasis area and severity index (pasi) score greater than or equal to 10 and body surface area (bsa) greater than or equal to 10% * must meet specific laboratory criteria * must be a candidate for photo/systemic therapy * women of childbearing potential must have a negative pregnancy test exclusion criteria: * must not have clinically significant underlying disease processes * must not be pregnant or lactating females * must not have any condition, including lab abnormalities, which places the subject at unacceptable risk if the subject were to participate in the study or confounds the ability to interpret data from the study * must not have a history of active mycobacterium tuberculosis infection within 3 years prior to the screening visit * must not have a history of incompletely treated active of latent mycobacterium tuberculosis infection * must not have a know history of exposure to an infectious case of mycobacterium tuberculosis within 2 years prior to the screening visit * must not be an immigrant form a high-incidence country for mycobacterium tuberculosis disease within 2 years prior to the screening visit * must not have current erythrodermic, guttate, or pustular psoriasis * must not have a clinical history of failure to adequately respond to treatment in the investigator's opinion to one or more treatment courses of cyclosporine or the following biologic therapies: alefacept, etanercept, efalizumab, infliximab or adalimumab * must not use topical therapy within 14 days of randomization * must not use systemic therapy for psoriasis within 28 days of randomization * must not use phototherapy within 28 days of randomization * must not use adalimumab or infliximab within 3 months of randomization * must not use etanercept or efalizumab within 56 days of randomization * must not use alefacept within 6 months of randomization

Keywords: plaque psoriasis
safety study of elotuzumab in combination with thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Conditions: Relapsed and/or Refractory Multiple Myeloma

Summary: the purpose of this study is to determine the safety and tolerability of elotuzumab administered in combination with thalidomide and dexamethasone in the treatment of relapsed and/or refractory multiple myeloma.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com. key inclusion criteria: * confirmed diagnosis of previously treated multiple myeloma with progression documented by criteria of the international myeloma working group after or during the most recent therapy * patient received 5 or fewer prior lines of therapy * eastern cooperative oncology group performance status of 0 or 1 (safety lead-in cohort) or 0 to 2 (additional patients) * measurable disease as defined by at least 1 of the following: * serum immunoglobulin (ig)g, iga, igm, or monoclonal (m) protein level ≥0.5 g/dl or serum igd m protein level ≥0.05 g/dl; or * urine m protein level ≥200 mg excreted in a 24-hour collection sample; or * involved serum free light chain level ≥10 mg/dl, provided the free light chain ratio is abnormal key exclusion criteria: * solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia * monoclonal gammopathy of undetermined significance, smoldering myeloma, or waldenström's macroglobulinemia * left ventricular ejection fraction by echocardiogram or multi gated acquisition ≤50% * electrocardiogram finding of qtc ≥450 msec * active plasma cell leukemia (defined as either 20% of peripheral white blood cells, composed of plasma/cd138+ cells or an absolute plasma cell count of 2\*10\^9/l) * diagnosis of nonsecretory myeloma * active hepatitis a, b, or c virus infection * grade ≥2 neuropathy
a cross over study to compare the effect of combined treatment with qav680 and cetirizine

Conditions: Allergic Rhinitis

Summary: this study will determine the capacity of more frequent dosing of qav680 to suppress allergic inflammation. the study will investigate the paradigm of multiple receptor antagonism in allergic disease by combining qav680 with a second generation h1 histamine receptor antagonist to assess possible additive or synergistic anti-allergic effects of the two compound classes.


Eligibility criteria:
inclusion criteria: * patients with clinical history of intermittent allergic rhinitis with seasonal onset and offset of nasal allergy symptoms during each of the last two ragweed allergy seasons * positive skin prick test to ragweed allergen within twelve months of screening exclusion criteria: * use of any medication used to treat allergy (administered via any route), such as: pseudoephedrine, antihistamines, ipratropium bromide, cromoglycates, corticosteroids, immunotherapy or other antiinflammatory or immunosuppressive agents, or any other medication administered via the nasal or ocular routes) * within the last three years a recurrent history of acute or chronic bronchospastic disease including moderate-severe asthma or chronic obstructive pulmonary disease * nasal conditions such as nasal septal perforations,nasal polyps, sinus disease, chronic nasal obstruction other protocol-defined inclusion/exclusion criteria may apply

Keywords: allergic inflammation seasonal rhinitis
high intensity multi-modal exercise training in postmenopausal women

Conditions: Postmenopausal Osteoporosis; Postmenopausal Osteopenia

Summary: in pakistan 9.9 million people are osteoporotic and 7.2 million amongst them are women. globally after every 3 seconds there is occurrence of fragility fracture.in pakistan females carries different risk factors based on distinct culture, environment, diet and lifestyle. so there is dire need to conduct more high quality clinical trials at national level in order to establish strong evidence in favor of low cost but highly effective exercise protocols for such a significant public health issue.

in postmenopausal age, women bones get weak and easily fracture after 50years. in pakistan every other female is silently suffering from this disease leading to bone, joint pain and disability. this project is innovatively designed first time in pakistan to target weak bones of women with high intensity, progressive exercise training. the objectives of this study are to determine the effects of a high intensity multi-modal exercise training on bone mineral density and functional performance in postmenopausal women. after initial screening based on history, subjective fracture risk calculations and subjective osteoporosis screening. females fulfilling criteria and willing to participate in exercise trial will be recruited in the study. at baseline, dexa scan will be done for femoral and lumbar bone density. all performance based testing for functional performance outcome measures would be done at baseline, after 3 months \& after 6 months. patient will be called twice a week for 8months and dexa will be repeated after 8months of training. it is hypothesized that supervised exercise training will improve bone mineral density and functional performance in postmenopausal women with low bone mass.

Eligibility criteria:
inclusion criteria: * postmenopausal women, at least 3 years since last mensuration. * age: 45-70years * body mass index (bmi) \<30kg/m2 * community ambulant without walking aid * good general health * willing for exercise therapy exclusion criteria: * history of fragility fracture in addition to bmd t-score of -2.5 or less * mmse \< 20 * taking hormone replacement therapy or steroids from last 1 year. * had participated in regular exercise for last 1 year * systemic illness: hyperthyroidism, hyperparathyroidism, diabetes mellitus, renal failure, any malignancy, extensive radiation exposure * any orthopedic injury/disorder hindering performance of exercise.
smartphone rehabilitation app for stroke survivor

Conditions: Stroke

Summary: this is a pilot study of a smartphone app in which the tool will be developed and validation of the tool will be done for the rehabilitation of upper limb in stroke survivors. the study will be divided into two phases. the first phase will be the development of a smartphone app for upper limb function. the second phase of the study will be a pilot study where 10 stroke patients will be recruited and upper limb intervention will be applied through a smartphone app.


Eligibility criteria:
inclusion criteria: * subacute and chronic stroke patient \> 3 months post stroke till 1 year. * modified ashworth scale scoring ≤ 2 * an ability to understand the command * first ever stroke * grade ii, iii on functional mobility scale * able to use and comprehend smart phone. exclusion criteria: * vestibular disorders, paroxysmal vertigo * presence of other neurological conditions such as neglect, hemianopsia and pushing syndrome

Keywords: stroke cva
cohort of hospitalized patients suspected of leptospirosis

Conditions: Leptospirosis

Summary: colept is a prospective interventional study that intends to better inform about leptospirosis, a neglected zoonotic infectious disease. during prospective follow-up of hospitalized acute leptospirosis cases, the participants will be assessed during 1 year for epidemiological, clinical, bacteriological and immunological data. main intervention consists in blood sampling and biological bank constitution.


Eligibility criteria:
inclusion criteria: * clinico-biological manifestations compatible with acute leptospirosis or proven leptospirosis with serological testing or pcr * onset of symptoms within 21 days * participant benefits of health insurance exclusion criteria: * participant's refusal, or refusal from his relatives in case of major incapacity of the eligible participant precluding expression of his will (coma, stay in intensive care unit))

Keywords: leptospirosis hospitalization
immobilization and neurological complications in patients with vertebral osteomyelitis.

Conditions: Vertebral Osteomyelitis; Spondylodiscitis

Summary: vertebral osteomyelitis is an infection of the intervertebral disk and adjacent vertebral plates with a non-negligible risk of neurological complications and handicap. if there are clear recommendations dealing with antibiotic therapy and surgery indications for this pathogen, the question of the immobilization will be remaining debate. the aim of the study was to describe protocols and practices for the immobilization of vertebral osteomyelitis in different french hospitals and bone and joint infections centers. the secondary objectives were to evaluate the frequency of neurological complications in a large prospective cohort, and to identify clinical and imaging risk factors for neurological complications. the investigators also aim to search for association between type and duration of spine immobilization and neurological status at the end of follow-up.

study design is descriptive, prospective, multicentric, and the investigators have a single database centralized in nantes university hospital. patient's data will be conserved and trapped anonymously and patients all give oral consent. information letter is given to each patient. typical study calendar : baseline : * patient information (letter and oral consent) * clinical data and comorbidities collection * neurological examination * spine x-ray * mri or ct-scan imaging to confirm diagnosis during hospitalization * date collection : spine immobilization modalities (type, duration, changes...), duration of bed rest * other treatments (antibiotic therapy : molecules and duration) * daily neurological examination 3 months follow-up visit : (if usually done by physician) * clinical and neurological examination * spine immobilization assessment * spine x-ray * oswestry questionary 6 months follow-up visit : finale visit (if usually done by physician) * clinical and neurological examination * spine immobilization assessment * spine x-ray * oswestry questionary

Eligibility criteria:
inclusion criteria: * adults patients, male and female * hospitalized of a vertebral osteomyelitis in one of the centers * meeting the criteria for the definition of vertebral osteomyelitis (typical imaging findings) * microbiological proof of infection (blood culture or discovertebral biopsy) or high suspicion of infection (compatible histology, good response to antibiotics and no differential diagnosis). exclusion criteria:- spine device infection * recent spinal surgery less than 1month * children under 18 years old * under guardianship * pregnant woman

Keywords: vertebral osteomyelitis spine immobilization neurological complications
preoperative ilux on cataract surgery derived dry eye disease due to meibomian gland dysfunction

Conditions: Dry Eye Disease; Meibomian Gland Dysfunction; Cataract Senile; Dry Eye Syndromes

Summary: this prospective study will investigate the effect of pre-operative systane ilux system administration in treated cataract induced dry eye disease.

eligible patients to be recruited will have scheduled upcoming senile cataract surgery. enrolled patients in the active arm (n=25) will receive pre-operative systane ilux treatment two weeks prior to surgery at the baseline visit. patients in the control arm will receive no systane ilux treatment at the baseline visit two weeks prior to cataract surgery. patients will be assessed on baseline metrics for dry eye disease stemming and meibomian gland dysfunction (mgd) at the baseline visit two weeks prior to cataract surgery. these metrics include tear break up time (tbut), standard patient evaluation of eye dryness questionnaire (speed), ocular surface and surface disease index (osdi) surveys, and lipid layer thickness (llt). at the follow up visit four weeks after cataract surgery, these same metrics will be assessed again for any significant changes.

Eligibility criteria:
inclusion criteria: * age greater than 18 at the time of informed consent * must understand; be willing and able, and likely to fully comply with study procedures, visit schedule, and restrictions * upcoming scheduled senile cataract surgery exclusion criteria: * eyelid abnormalities * patients with active ocular infection, active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months * ocular surgery within the last 6 months * occlusion therapy with lacrimal or punctum plugs within the last 3 months * patients with an ocular surface abnormality that may compromise corneal integrity * patients with ocular injury or trauma, chemical burns, or limbal stem cell deficiency (within prior 3 months) * patients with cicatricial lid margin disease * patients with lid surface abnormalities that affect lid function in either eye; patients with aphakia * patients with permanent makeup or tattoos on their eyelids. * previous application/administration of systane ilux or lipiflow treatment